We are live on ! Find out more
LVAC

LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC

Delisted

LVAC was delisted on the 10th of May, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 54 → 0 (-54)

100% less capital invested

Capital invested by funds: $116M → $0 (-$116M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 54

Holders
–
Holders Change
-54
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
54
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
-$11.2M
2
PC
Periscope Capital
Ontario, Canada
-$10.1M
3
SCM
Shaolin Capital Management
Florida
-$9.28M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
-$7.8M
5
CCA
Castle Creek Arbitrage
Colorado
-$6.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Clear Street
New York
– -$24K -2,300 Closed
Barclays
52
Barclays
United Kingdom
– -$6.26K -600 Closed
Deutsche Bank
53
Deutsche Bank
Germany
– -$5.99K -574 Closed
TRCT
54
Tower Research Capital (TRC)
New York
– -$2K -195 Closed
1 2
3

LVAC Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q2 2023, worth a combined $0 — down 100% from $116M a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of LVAC and 0 opened new positions — a net loss of 54 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Saba Capital Management, exiting entirely with an estimated $11.2M sold.

  • 0 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q2 2023, down from 54 in Q1 2023.
  • Funds reported $0 of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q2 2023 and 54 closed out, a net change of -54 holders.
  • The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q2 2023 was Saba Capital Management, an estimated $11.2M sold.

Based on aggregated 13F filings for Q2 2023.